Growth After Menarche in Pediatric Inflammatory Bowel Disease.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pmc-release:
01
02
2024
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
1
2
2023
Statut:
ppublish
Résumé
Growth impairment in pediatric patients with pediatric onset inflammatory bowel disease (IBD) is multifactorial. Reports on the effect of age at menarche on adult stature in this population are limited. This study investigated the impact of age at menarche, disease-associated factors, and mid-parental height on growth from menarche to final height (FHt) in pediatric patients with Crohn disease (CD) and ulcerative colitis (UC) and IBD unclassified (IBD-U). Subjects were enrolled from a prospectively maintained pediatric IBD database when IBD preceded menarche and dates of menarche and FHt measurements were recorded. One hundred forty-six patients: CD 112 and UC 30/IBD-U 4. Mean age (years) at diagnosis (10.9 vs 10.1), menarche (14.4 vs 14.0), and FHt (19.6 vs 19.7). CD and UC/IBD-U patients showed significant association between Chronological age (CA) at menarche and FHt (cm, P < 0.001) but not FHt z score (FHt-Z) < -1.0 (P = 0.42). FHt-Z < -2.0 occurred in only 5 patients. Growth impairment (FHt-Z < -1.0) was associated with surgery before menarche (P = 0.03), jejunal disease (P = 0.003), low mid-parental height z score (MPH-Z) (P < 0.001), hospitalization for CD (P = 0.03) but not UC, recurrent corticosteroid, or anti-tumor necrosis factor alpha (anti-TNFα) therapy. Early age of menarche was associated with greater potential for linear growth to FHt but not FHt-Z (P < 0.05). Surgery before menarche, jejunal disease, hospitalization for CD, low MPH, and weight z score were associated with FHt-Z < -1.0.
Identifiants
pubmed: 36705699
doi: 10.1097/MPG.0000000000003667
pii: 00005176-202302000-00015
pmc: PMC9889107
mid: NIHMS1852953
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-190Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM007019
Pays : United States
Informations de copyright
Copyright © 2022 by European Society for European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Kirschner BS, Voinchet O, Rosenberg IH. Growth retardation in inflammatory bowel disease. Gastroenterology. 1978;75:504–11.
Lee JJ, Escher JC, Shuman MJ, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669–77.
Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014;11:601–10.
Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut. 1993;34:939–43.
Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168–74.
Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Menarche in pediatric patients with Crohn’s disease. Dig Dis Sci. 2012;57:2975–81.
Gupta N, Lustig RH, Andrews H, et al. Introduction to and screening visit results of the multicenter pediatric Crohn’s disease growth study. Inflamm Bowel Dis. 2020;26:1945–50.
Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18:165–73.
Taminiau JA. Review article: The clinical importance of growth in children with inflammatory bowel disease: is it important to the gastroenterologist? Aliment Pharmacol Ther. 2007;26(Suppl 2):53–6.
Herzer M, Denson LA, Baldassano RN, Hommel KA. Patient and parent psychosocial factors associated with health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:295–9.
Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 2006;118:124–9.
Academy of Nutrition and Dietetics. Nutricare-tools. Available at: https://www.eatrightstore.org/product-type/subscriptions/nutricare-tools . Accessed July 22, 2022
Control CfD. CDC standard deviation-derived growth reference curves derived from NCHS/CDC reference population. NCHS growth curves for children, birth to 18 years. US. Available at: https://www.cdc.gov/nccdphp/dnpao/growthcharts/training/overview/page4.html . Accessed June 28, 2021
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.
Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–74.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A5a–36A.
Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423–41.
Ley D, Duhamel A, Behal H, et al. Growth pattern in paediatric Crohn disease is related to inflammatory status. J Pediatr Gastroenterol Nutr. 2016;63:637–43.
Assa A, Assayag N, Balicer RD, et al. Pediatric-onset inflammatory bowel disease has only a modest effect on final growth: a report from the epi-IIRN. J Pediatr Gastroenterol Nutr. 2021;73:223–30.
Duchatellier CF, Kumar R, Krupoves A, Braegger C, Herzog D, Amre DK. Steroid administration and growth impairment in children with Crohn’s disease. Inflamm Bowel Dis. 2016;22:355–63.
Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2–9 years allowing for heights of parents. Arch Dis Child. 1970;45:755–62.
Hintz RL. Final height prediction in constitutional growth delay. J Pediatr Endocrinol Metab. 2001;14(Suppl 6):1535–40.
Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ. 1994;308:1259–63.
Mason A, Malik S, McMillan M, et al. A prospective longitudinal study of growth and pubertal progress in adolescents with inflammatory bowel disease. Horm Res Paediatr. 2015;83:45–54.
Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995–1000.
Martinez GM. Trends and patterns in menarche in the United States: 1995 through 2013–2017. Natl Health Stat Report. 2020;146:1–12.
Gupta N, Liu C, King E, et al. Continued statural growth in older adolescents and young adults with Crohn’s disease and ulcerative colitis beyond the time of expected growth plate closure. Inflamm Bowel Dis. 2020;26:1880–9.
Herzog D, Fournier N, Buehr P, et al. Early-onset Crohn’s disease is a risk factor for smaller final height. Eur J Gastroenterol Hepatol. 2014;26:1234–9.
Karlberg J, Fryer JG, Engström I, et al. Analysis of linear growth using a mathematical model. II. From 3 to 21 years of age. Acta Paediatr Scand Suppl. 1987;337:12–29.
Zacharias L, Rand WM, Wurtman RJ. A prospective study of sexual development and growth in American girls: the statistics of menarchie. Obstet Gynecol Surv. 1976;31:325–37.
Karlberg J. Secular trends in pubertal development. Horm Res. 2002;57(Suppl 2):19–30.
Wine E, Reif SS, Leshinsky-Silver E, et al. Pediatric Crohn’s disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics. 2004;114:1281–6.
Attard TM, Horton KM, DeVito K, et al. Pediatric jejunoileitis: a severe Crohn’s disease phenotype that requires intensive nutritional management. Inflamm Bowel Dis. 2004;10:357–60.
Ricciuto A, Aardoom M, Orlanski-Meyer E, et al. Predicting outcomes in pediatric Crohn’s disease for management optimization: systematic review and consensus statements from the pediatric inflammatory bowel disease-ahead program. Gastroenterology. 2021;160:403–436.e26.
Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105:681–91.
Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion. 2012;85:308–19.
Alemzadeh N, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CBHW, van Hogezand RA. Adult height in patients with early onset of Crohn’s disease. Gut. 2002;51:26–9.
Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr. 2001;33:75–80.
Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn’s disease. Rev Gastroenterol Disord. 2003;3(Suppl 1):S23–9.
Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al. Nutritional status and growth in pediatric Crohn’s disease: a population-based study. Am J Gastroenterol. 2010;105:1893–900.
Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body composition, and nutritional status in children and adolescents with Crohn’s disease. J Pediatr Gastroenterol Nutr. 2000;31:33–40.
Mouratidou N, Malmborg P, Sachs MC, et al. Adult height in patients with childhood-onset inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2020;51:789–800.
Carroll MW, Kuenzig ME, Mack DR, et al. The impact of inflammatory bowel disease in Canada 2018: children and adolescents with IBD. J Can Assoc Gastroenterol. 2019;2:S49–67.
DeGreef E, Hoffman I, Smets F, et al. Paediatric Crohn disease: disease activity and growth in the BELCRO cohort after 3 years follow-up. J Pediatr Gastroenterol Nutr. 2016;63:253–8
Rinawi F, Popalis C, Tersigni C, et al. Long-term outcomes with adalimumab therapy in pediatric Crohn disease: associations with adalimumab exposure. J Pediatr Gastroenterol Nutr. 2022;74:389–95.
Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373–80.
Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl. 1990;366:98–104; discussion 105.
Himes JH, Roche AF, Thissen D, Moore WM. Parent-specific adjustments for evaluation of recumbent length and stature of children. Pediatrics. 1985;75:304–13.
Crombé V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study. Inflamm Bowel Dis. 2011;17:2144–52.
Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, et al. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis. 2013;19:1218–23.